Multimer Detection System-Oligomerized Amyloid Beta (MDS-OAβ): A Plasma-Based Biomarker Differentiates Alzheimer’s Disease from Other Etiologies of Dementia

• Published in: International journal of alzheimer's disease Vol. 2022; pp. 9960832 - 6
• Main Authors: Dominguez, Jacqueline Cotoong, Yu, Jeryl Ritzi Tan, De Guzman, Ma Fe, Ampil, Encarnita, Guevarra, Anne Cristine, Joson, Ma. Lourdes, Reandelar, Macario, Martinez, Ma. Socorro, Ligsay, Antonio, Ocampo, Ferron, Kim, SangYun
• Format: Journal Article
• Language: English
• Published: United States Hindawi 2022; Hindawi Limited
• Subjects: Age groups; Alzheimer's disease; Biomarkers; Blood tests; Cognitive ability; Dementia; Dementia disorders; Enzymes; Etiology; Hypotheses; Impairment; Memory; Neurodegenerative diseases; Neuropsychology; Older people; Oligomerization; Plasma; Sample size; Variance analysis; Vascular dementia; β-Amyloid
• ISSN: 2090-8024; 2090-0252
• DOI: 10.1155/2022/9960832

With emerging amyloid therapies, documentation of the patient’s amyloid status to confirm the etiology of a clinical diagnosis is warranted prior to instituting amyloid-based therapy. The Multimer Detection System-Oligomeric Amyloid-β (MDS-OAβ) is a noninvasive blood-based biomarker utilized to measure Aβ oligomerization tendency. We determined the difference in MDS-OAβ ratio across the groups: (a) no cognitive impairment or subjective cognitive impairment (NCI/SCI), (b) Alzheimer’s disease (AD), (c) non-AD, and (d) mixed Alzheimer’s disease-Vascular dementia (AD-VaD). MDS-OAβ level was not significantly different between AD and mixed AD-VaD, but both groups were significantly different from the NCI/SCI and from the non-AD group. An MDS-OAβ level of >1 could potentially indicate clinical variants of AD or mixed pathology (AD-VaD).